Loading
Latest filing published 23 May 2022 for Inhibikase Therapeutics, Inc., €2,403.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
This profile gathers the share dealings of Joseph Frattaroli in Inhibikase Therapeutics, Inc., where the filings describe the role as finance chief. We count 2 filings; the first trade dates from 28 December 2020 and the latest from 19 May 2022.
No open-market sale appears; the market trades are 1 purchase worth €2,403. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2022: 1 purchase and no sales on the market.
On 23 May 2022 came the latest disclosure, an open-market purchase for €2,403 in Inhibikase Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration